Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alnylam Pharmaceuticals Inc ALNY

Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for... see more

Recent & Breaking News (NDAQ:ALNY)

Alnylam Reports Positive Initial Clinical Results for ALN-CC5, an Investigational RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases

Business Wire June 12, 2015

Alnylam Files Trade Secret Misappropriation Suit Against Dicerna Pharmaceuticals

Business Wire June 10, 2015

Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer

Business Wire June 8, 2015

Alnylam to Present New Data at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress with ALN-AT3, an Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)

Business Wire June 5, 2015

Alnylam to Webcast Presentations at Upcoming June Investor Conferences

Business Wire May 28, 2015

Alnylam Initiates Phase 1 Clinical Trial for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP)

Business Wire May 26, 2015

Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for Revusiran, an Investigational RNAi Therapeutic for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Business Wire May 20, 2015

Alnylam Files Clinical Trial Application (CTA) for ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

Business Wire May 17, 2015

Alnylam Pharmaceuticals Reports First Quarter 2015 Financial Results and Highlights Recent Period Progress

Business Wire May 7, 2015

Alnylam to Webcast Conference Call Discussing First Quarter 2015 Financial Results

Business Wire April 30, 2015

Alnylam to Webcast Presentations at Upcoming May Investor Conferences

Business Wire April 29, 2015

Alnylam Reports 12-Month Clinical Data from Phase 2 Open Label Extension (OLE) Study of Patisiran, an Investigational RNAi Therapeutic for Patients with Familial Amyloidotic Polyneuropathy (FAP)

Business Wire April 21, 2015

Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3, an Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)

Business Wire April 13, 2015

Alnylam to Webcast Presentation at 14th Annual Needham Healthcare Conference

Business Wire April 8, 2015

Alnylam Presents Results from Natural History Study of Patients with Familial Amyloidotic Cardiomyopathy (FAC) and Presents Complete Results from Phase 2 Clinical Trial for Revusiran, an Investigational RNAi Therapeutic for the Treatment of FAC

Business Wire March 15, 2015

Alnylam to Webcast Presentation at 22nd Annual Future Leaders in the Biotech Industry Conference

Business Wire March 13, 2015

Alnylam to Webcast Presentation at Barclays Global Healthcare Conference

Business Wire March 5, 2015

Warp Drive Bio Appoints Industry Veteran Laurence Reid, Ph.D., to Chief Executive Officer

Business Wire March 4, 2015

Alnylam to Webcast Presentation at Cowen & Company 35th Annual Health Care Conference

Business Wire February 25, 2015

Alnylam to Webcast Presentation at 2015 RBC Capital Markets' Global Healthcare Conference

Business Wire February 18, 2015